PM
BBIO icon

Parametrica Management’s BridgeBio Pharma BBIO Stock Holding History

Parametrica Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-4,250
Closed -$251K – 105
2021
Q1 		$251K Buy
+4,250
New +$278K 0.12% 126

Other funds holding BBIO

KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Parametrica Management's BBIO Position: Q2 2021 in Review

Parametrica Management sold out of BridgeBio Pharma (BBIO) in Q2 2021, closing a stake of 4,250 shares — an estimated $251K sold.

Parametrica Management first reported a position in BBIO in Q1 2021 and held it in 1 quarter. The position peaked at $251K in Q1 2021. 200 funds tracked by Wall St. Rank hold BBIO as of Q2 2021.

  • Parametrica Management reported no remaining BridgeBio Pharma position as of Q2 2021 after selling out during the quarter.
  • Parametrica Management sold 4,250 BridgeBio Pharma shares in Q2 2021, an estimated $251K.
  • Parametrica Management first reported a position in BridgeBio Pharma in Q1 2021 and held it in 1 quarter.
  • Parametrica Management's BridgeBio Pharma position peaked at $251K in Q1 2021.
  • 200 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2021.

Based on Parametrica Management's 13F filing for Q2 2021, filed 13 Aug 2021.